Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Long-term evaluation of opioid treatment in Fibromyalgia

Monday 10 February 2014

 

From ProHealth:

 

Tablets
 

Long-Term Evaluation of Opioid Treatment in Fibromyalgia.

By Xiaomei Peng, MD, PhD, et al.
www.ProHealth.com
February 6, 2014

Abstract:

OBJECTIVES In a 12-month observational study, we evaluated the effect of opioid use on outcomes in 1700 adult patients with fibromyalgia (FM).

METHODS: Data were evaluated using propensity-score-matching after patients were divided into cohorts based on their baseline medication use: (1) taking an opioid (concurrent use of tramadol was permitted); (2) taking tramadol (but no opioids); and (3) not taking opioids or tramadol. Changes in outcomes were assessed using the

  • Brief Pain Inventory for severity and pain-related interference (BPI-S, BPI-I),

  • Fibromyalgia Impact Questionnaire (FIQ),

  • Patient Health Questionnaire for depression (PHQ-8),

  • Insomnia Severity Index (ISI),

  • Sheehan Disability Scale (SDS),

  • 7-item Generalized Anxiety Disorder scale (GAD-7)

  • and economic factors.

Time to opioid or tramadol discontinuation was analyzed using Kaplan-Meier survival analyses.

RESULTS:

  • Compared with the opioid cohort, the non-opioid cohort demonstrated significantly greater reductions (P<0.05) in BPI-I, FIQ, PHQ-8, SDS and ISI;

  • the tramadol cohort compared with the opioid group showed greater reductions on FIQ and ISI.

  • Reductions in BPI-S and GAD-7 did not differ significantly among cohorts.

  • Compared with the opioid cohort, patients in the tramadol cohort had fewer outpatient visits to healthcare providers.

  • Few significant differences were found between the tramadol and non-opioid cohorts across outcomes.

DISCUSSION: While pain severity was reduced over time in all cohorts, opioid users showed less improvement in pain-related interference with daily living, functioning, depression, and insomnia. Overall, the findings show little support for the long-term use of opioid medications in patients with FM given the poorer outcomes across multiple assessment domains associated with this cohort.

Source: The Clinical Journal of Pain, January 28, 2014. By Peng, Xiaomei MD, PhD; Robinson, Rebecca L. MS; Mease, Philip MD; Kroenke, Kurt MD; Williams, David A. PhD; Chen, Yi MS; Faries, Douglas PhD; Wohlreich, Madelaine MD; McCarberg, Bill MD; Hann, Danette PhD.

 

The above originally appeared here.

 


 

blog comments powered by Disqus
Previous Previous Page